Our study’s evaluation of the effect of biomarkers on the pCR outcome suggested the commonly reported biomarkers ER, PR, HER2, and Ki-67 as predictors of the likelihood of better pCR outcomes in breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.